Skip to main content
. 2018 Oct 2;9:2242. doi: 10.3389/fimmu.2018.02242

Table 2.

Study population for B-cell phenotyping.

Healthy control AAV remission AAV active p-value
Number of individuals: n (female/male) 31 (17/14) 34 (19/15) 28 (11/17) 0.361
Age: median years (range) 60 (26–85) 69 (22–87) 65 (29–93) 0.085
ANCA at diagnosis: PR3/MPO na 25/9 17/11 0.413
GPA/MPA na 25/9 19/9 0.779
Disease onset/relapse na na 19/9
ORGAN INVOLVEMENT:
   ENT, n (%) [ever/sample] na 23 (68) [23/na] 14 (50) [14/14] 0.198
   Lungs, n (%) [ever/sample] na 14 (41) [14/na] 14 (50) [14/9] 0.610
   Kidneyes, n (%) [ever/sample] na 19 (56) [19/na] 21 (75) [21/16] 0.182
   Nervous system, n (%) [ever/sample] na 10 (29) [10/na] 10 (36) [10/6] 0.785
TREATMENT AT TIME OF SAMPLING:
Prednisolone, n (%) na 22 (65) 14 (50) 0.345
Prednisolone, median mg/day (range) na 2.5 (0–13) 1.3 (0–30) 0.979
Azathioprine, n (%) na 8 (24) 1 (3.6) 0.033
Methotrexate, n (%) na 10 (29) 3 (11) 0.116
Mycophenolate mofetil n (%) na 4 (12) 1 (3.6) 0.366
No immunosuppressive therapy, n (%) na 3 (9) 14 (50) 0.0004
PRIOR TREATMENT:
Cyclophosphamide: n (%) na 30 (88) 7 (25) < 0.0001
Rituximab: n (%) na 11 (32) 5 (18) 0.250
   Time since rituximab at sampling in treated patients: median months (range) na 26 (7–86) 18 (11–94) 0.935
Neither cyclophosphamide or rituximab: n (%) na 2 (6) 20 (71) < 0.0001
BVAS: median (range) na 0 14 (2–26)

AAV, ANCA-associated vasculitis; PR3, proteinase 3; MPO, myeloperoxidase; GPA, granulomatous with polyangiitis; MPA, microscopic polyangiitis; ENT, ear, nose and throat; BVAS, Birmingham vasculitis activity score; na, not applicable.

Fisher's exact test or the Chi-squared test were used to compare discrete variables and Mann-Whitney U test or the Kruskal-wallis test followed by Dunn's multiple comparison test were used to compare continuous variables between the groups.

Significance assumed at p < 0.05.